Gan & Lee Pharmaceuticals.
Clinical trials sponsored by Gan & Lee Pharmaceuticals., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New insulin rival: can GZR4 beat current options for diabetes? Results expected Nov 2026 (estimated)
- New diabetes shot GZR18 takes on semaglutide in major trial Results expected Dec 2026 (estimated)
- New diabetes shot aims to help when pills or insulin fall short Results expected Feb 2027 (estimated)
- New Weight-Loss drug GZR18 takes on wegovy in major trial Results expected Jun 2027 (estimated)
- Could a pill help tackle obesity? new drug enters human testing Results expected Aug 2027 (estimated)
-
Could a pill help tackle obesity? new drug enters human testing
Disease control Not yet recruitingThis early-stage trial tests an experimental oral drug called GZC8072 in two groups: healthy adults receiving a single dose, and people with overweight or obesity receiving multiple doses. The main goals are to assess the drug's safety, how the body processes it, and its effects …
Phase 1 • Sponsor: Gan & Lee Pharmaceuticals. • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
New diabetes shot aims to help when pills or insulin fall short
Disease control Not yet recruitingThis study tests a new injectable medicine, GZR101-80, for people with type 2 diabetes that is not well controlled by current pills or basal insulin. About 345 adults will receive the drug for 16 weeks to see if it lowers blood sugar and HbA1c safely. The goal is better daily con…
Phase 2 • Sponsor: Gan & Lee Pharmaceuticals. • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New injection could ease sleep apnea and aid weight loss
Disease control Not yet recruitingThis study tests an injection called GZR18 in 140 obese adults with moderate-to-severe obstructive sleep apnea who already use a breathing machine (PAP). The goal is to see if the drug improves breathing during sleep, reduces weight, and boosts quality of life compared to a place…
Phase 3 • Sponsor: Gan & Lee Pharmaceuticals. • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New shot could help obese patients breathe better at night without CPAP
Disease control Not yet recruitingThis study tests an injection called GZR18 in 140 obese adults with moderate to severe obstructive sleep apnea who cannot or will not use a CPAP machine. The goal is to see if the drug improves breathing during sleep and helps with weight loss over 52 weeks. Participants will rec…
Phase 3 • Sponsor: Gan & Lee Pharmaceuticals. • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New hope for metastatic prostate cancer? early trial of GLR2037 begins
Disease control Not yet recruitingThis early-stage trial is testing an experimental drug called GLR2037 in 65 men with metastatic prostate cancer that has spread to bones or soft tissues. The main goals are to check the drug's safety and how the body processes it. Participants will take GLR2037 daily in 28-day cy…
Phase 1 • Sponsor: Gan & Lee Pharmaceuticals. • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Healthy volunteers to test two batches of new diabetes drug
Knowledge-focused Not yet recruitingThis early-stage trial will check whether two different ways of making the experimental drug GZR4 produce the same levels in the blood. About 64 healthy men will receive a single shot of one version or the other. The study is not designed to treat diabetes, but to ensure future b…
Phase 1 • Sponsor: Gan & Lee Pharmaceuticals. • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
Could a cheaper dupixent be on the horizon? early trial launches
Knowledge-focused Not yet recruitingThis early-stage trial will test whether a new injection called GLR1044 works like the approved drug Dupixent in the body. About 198 healthy Chinese men will receive a single dose of either GLR1044 or Dupixent. Researchers will compare how the drugs are absorbed and processed, an…
Phase 1 • Sponsor: Gan & Lee Pharmaceuticals. • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:10 UTC